Trials / Completed
CompletedNCT02787239
Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 407 (actual)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter, Randomized, Double-blind, Parallel, Phase III Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and MabThera in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HLX01 | |
| DRUG | Rituximab | |
| DRUG | CHOP |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2018-05-01
- Completion
- 2018-05-01
- First posted
- 2016-06-01
- Last updated
- 2022-05-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02787239. Inclusion in this directory is not an endorsement.